Details
Stereochemistry | MIXED |
Molecular Formula | C19H32NO2.Br |
Molecular Weight | 386.367 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].CCC(C)C(C(=O)OCC[N+](C)(CC)CC)C1=CC=CC=C1
InChI
InChIKey=CEJGGHKJHDHLAZ-UHFFFAOYSA-M
InChI=1S/C19H32NO2.BrH/c1-6-16(4)18(17-12-10-9-11-13-17)19(21)22-15-14-20(5,7-2)8-3;/h9-13,16,18H,6-8,14-15H2,1-5H3;1H/q+1;/p-1
Molecular Formula | BrH |
Molecular Weight | 80.912 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C19H32NO2 |
Molecular Weight | 306.4629 |
Charge | 1 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1635586Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/valethamate-bromide.html | https://www.ncbi.nlm.nih.gov/pubmed/19664769 | https://www.ncbi.nlm.nih.gov/pubmed/26291425
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1635586
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/valethamate-bromide.html | https://www.ncbi.nlm.nih.gov/pubmed/19664769 | https://www.ncbi.nlm.nih.gov/pubmed/26291425
Valethamate bromide ( sold under many brand names such as Epidosin, Dilaton, Valosin, Valamate, Osdil etc), a quarternary ammonium agent, has been used in augmentation of labor. Valethamate has antimuscarinic action and blocks cholinergic receptors in the ganglia. This action along with the direct action on the smooth muscles of the cervix is thought to help cervical dilatation during labor. Since it is not selective, it exerts anticholinergic side effects such as tachycardia, flushing, cotton mouth and photophobia due to mydriasis. Common side effects are palpitations, increased heart rate, arrhythmia, excessive thirst, reduced bronchial secretions, dry mouth, Photophobia, dry skin, loss of accommodation, slow heart rate, flushing.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1635586 |
|||
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1635586 |
|||
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1635586 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | EPIDOSIN Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
8 mg 2 times / hour multiple, intravenous Highest studied dose Dose: 8 mg, 2 times / hour Route: intravenous Route: multiple Dose: 8 mg, 2 times / hour Sources: Page: Page 13676 |
healthy, 20-30 n = 50 Health Status: healthy Condition: Labour Age Group: 20-30 Sex: F Population Size: 50 Sources: Page: Page 13676 |
|
60 mg single, intravenous|intramuscular Toxic dose Dose: 60 mg Route: intravenous|intramuscular Route: single Dose: 60 mg Sources: Page: Page 13674 |
healthy Health Status: healthy Condition: Labour Sex: F Sources: Page: Page 13674 |
Disc. AE: Circulatory failure, Respiratory failure... AEs leading to discontinuation/dose reduction: Circulatory failure (grade 5, very rare) Sources: Page: Page 13674Respiratory failure (grade 5, very rare) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Circulatory failure | grade 5, very rare Disc. AE |
60 mg single, intravenous|intramuscular Toxic dose Dose: 60 mg Route: intravenous|intramuscular Route: single Dose: 60 mg Sources: Page: Page 13674 |
healthy Health Status: healthy Condition: Labour Sex: F Sources: Page: Page 13674 |
Respiratory failure | grade 5, very rare Disc. AE |
60 mg single, intravenous|intramuscular Toxic dose Dose: 60 mg Route: intravenous|intramuscular Route: single Dose: 60 mg Sources: Page: Page 13674 |
healthy Health Status: healthy Condition: Labour Sex: F Sources: Page: Page 13674 |
PubMed
Title | Date | PubMed |
---|---|---|
Drotaverine hydrochloride vs. valethamate bromide in acceleration of labor. | 2001 Sep |
|
Comparison of domiciliary and institutional delivery-care practices in rural Rajasthan, India. | 2009 Apr |
|
Meperidine versus valethamate bromide in shortening the duration of active labor. | 2009 Nov |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Valethamate bromide: Is there any proof of efficacy and safety for its use in labor? | 2010 Jan |
|
Author's reply. | 2010 Jul |
|
A randomised controlled study comparing Drotaverine hydrochloride and Valethamate bromide in the augmentation of labour. | 2010 Jul |
Patents
Sample Use Guides
Adult- PO- Per tab contains valethamate bromide 10 mg and paracetamol 325 mg: 1 tab 3 times/day.
IV/IM- 8-16 mg/day.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1635586
The contraction of uterine horns from immature guinea pigs in response to methacholine (isotonic recording) was used for activity evaluztion. The uterine horns were suspended in an organ bath under 1 g resting tension and were superfused with SUND's physiological salt solution at a rate of 2 mi/min . After an equilibration period of 60 rain, 4 cumulative concentration-response curves to methacholine were obtained in each preparation at 60 or 90 min intervals. The first curve served as a control for the following curves which were carried out in the absence or presence of increasing concentrations of a given antagonist (60 or 90 min equilibration time).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:22:29 GMT 2023
by
admin
on
Fri Dec 15 15:22:29 GMT 2023
|
Record UNII |
6XFR940M2A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
90-22-2
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
6XFR940M2A
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
201-977-8
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL2111176
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
7010
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
SUB15685MIG
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
100000076983
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
DBSALT002829
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
DTXSID5049027
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | |||
|
m11362
Created by
admin on Fri Dec 15 15:22:29 GMT 2023 , Edited by admin on Fri Dec 15 15:22:29 GMT 2023
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |